Acupoint Application for Chemotherapy-Induced Nausea and Vomiting in Lung Cancer

NCT07768124 | Recruiting

• 1 other identifier: XWFT-2025-001
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This single-center, randomized, controlled study evaluates whether acupoint application added to standard 5-HT3 receptor antagonist anti-nausea medication improves control of chemotherapy-induced nausea and vomiting in adults with lung cancer receiving first-line platinum-based chemotherapy. Participants will be randomly assigned to receive either acupoint application plus a 5-HT3 receptor antagonist or the 5-HT3 receptor antagonist alone for one chemotherapy cycle. The study will compare complete control of delayed nausea and vomiting between the two groups.

Conditions

Lung Cancer (Diagnosis)Chemotherapy-Induced Nausea and Vomiting

Keywords

acupoint application; 5-HT3 receptor antagonist; chemotherapy-induced nausea and vomiting; lung cancer; randomized controlled trial; supportive care

Outcome Measures

Primary Outcomes (1)

• Complete response rate of delayed-phase CINV (24-120 h)

  Complete response is defined as no emetic episodes and no rescue antiemetic use during 24 to 120 hours after the first cycle of platinum-based chemotherapy. The outcome will be compared between the acupoint application plus 5-HT3 receptor antagonist group and the 5-HT3 receptor antagonist alone group.

  24 to 120 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

Secondary Outcomes (3)

• Complete response rate of acute-phase CINV (0-24 h)

  0 to 24 hours after the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

• MAT nausea score

  During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

• FLIE quality-of-life score

  During the first cycle of platinum-based chemotherapy (each cycle is 21-28 days)

Study Arms (2)

Acupoint application plus 5-HT3 receptor antagonist

EXPERIMENTAL

Participants receive herbal acupoint plaster applied to selected acupoints plus standard 5-HT3 receptor antagonist prophylaxis before and during one cycle of platinum-based chemotherapy.

Drug: 5-HT3 receptor antagonist (e.g., ondansetron); Other: Acupoint application

5-HT3 receptor antagonist alone

ACTIVE COMPARATOR

Participants receive standard 5-HT3 receptor antagonist prophylaxis alone before and during one cycle of platinum-based chemotherapy.

Drug: 5-HT3 receptor antagonist (e.g., ondansetron)

Interventions

5-HT3 receptor antagonist (e.g., ondansetron) DRUG

Standard antiemetic prophylaxis for chemotherapy-induced nausea and vomiting.

5-HT3 receptor antagonist alone; Acupoint application plus 5-HT3 receptor antagonist

Acupoint application OTHER

Herbal plaster applied to selected acupoints to alleviate chemotherapy-induced nausea and vomiting.

Acupoint application plus 5-HT3 receptor antagonist

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Pathologically or cytologically confirmed lung cancer.
• Scheduled to receive first-line platinum-based chemotherapy.
• Aged 18 to 75 years.
• Karnofsky Performance Status (KPS) score ≥ 60.
• Expected survival ≥ 3 months.
• Voluntarily signed written informed consent.

You may not qualify if:

• Known allergy to any component of the acupoint plaster.
• Severe skin disease, infection, or breakdown at the planned acupoint sites. --Pregnant or lactating women.
• Cognitive impairment or psychiatric disorder that prevents completion of study assessments.
• Participation in another interventional clinical trial within 30 days prior to enrollment.

Sponsors & Collaborators

• Xiu Huang: lead

Study Sites (1)

The Affiliated Yongchuan Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 402160, China

RECRUITING

MeSH Terms

Conditions

Lung Neoplasms; Vomiting

Interventions

Ondansetron

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Signs and Symptoms, Digestive; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Imidazoles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Carbazoles; Indoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds, 3-Ring

Central Study Contacts

XIU HUANG

CONTACT

+8615023119040; 104100275@qq.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Chief Physician, Department of Oncology

Study Record Dates

• First Submitted: August 11, 2026
• First Posted: August 17, 2026
• Study Start: July 15, 2026
• Primary Completion (Estimated): October 15, 2026
• Study Completion (Estimated): October 15, 2026
• Last Updated: August 17, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will share

Locations

CN (1)